SecBot SecBot
Biotech Drug Report Generated Nov 16, 2026

ABV-1504

ABVC·ABVC BIOPHARMA, INC.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical / Early-stage (no registered clinical trials found)
Time to market
Not stated
Why 2/10
No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for ABV-1504 in the next ~12 months. The drug appears to be in preclinical or very early-stage development with no registered clinical trials found. ABVC has multiple pipeline assets, so ABV-1504 is not a single make-or-break program.
Actionable Insight NEUTRAL

ABV-1504 has no near-term binary catalyst scheduled. The next meaningful event would be a clinical trial initiation or update from ABVC or its Chinese licensee Xinnovation Therapeutics, but no such date is publicly available. Watch for any press releases on Phase 2/3 trial starts or licensing milestone payments.

Price Chart

Loading chart...

Executive Summary

ABV-1504 is a natural/botanical drug candidate for Major Depressive Disorder (MDD) being developed by ABVC BioPharma (NASDAQ: ABVC), a clinical-stage micro-cap biopharmaceutical company. The drug has secured US and Japanese patent protection and was licensed to Xinnovation Therapeutics for the Chinese market in August 2023 under a deal with up to $20M in licensing fees and 5-12% royalties. However, no clinical trial records were found for ABV-1504, suggesting it remains in preclinical or very early-stage development. ABVC itself faces severe financial headwinds: zero revenue, a going concern warning, a working capital deficit, and reliance on dilutive financings. With no near-term binary catalyst, ABV-1504 is a high-risk, early-stage asset within a financially strained company.

How It Works

ABV-1504 is a natural/botanical drug candidate being developed to treat Major Depressive Disorder (MDD). It is part of ABVC's CNS (central nervous system) pipeline. The exact mechanism of action has not been publicly detailed, but as a botanical product, it is derived from plant-based sources.

Trial Status

No clinical trial records for ABV-1504 were found in the SecBot or ClinicalTrials.gov databases. The company has indicated it is eyeing Phase III trials for its depression therapies, but no trial initiations or data readouts have been publicly announced.

The Two-Sided Case

▲ Bull Case3
ABV-1504 has secured patent protection in both the US (Notice of Allowance received October 2022) and Japan (patent secured May 2025), providing intellectual property coverage in key pharmaceutical markets.
ABVC signed a licensing term sheet with Xinnovation Therapeutics in August 2023 for the Chinese market, with potential licensing fees of up to $20M and royalties of 5-12% of net sales, which could provide non-dilutive funding if milestones are met.
The drug is a natural/botanical treatment for Major Depressive Disorder (MDD), a large and growing market, and the company has indicated it is eyeing Phase III trials for its depression therapies.
▼ Bear Case4
ABVC is a micro-cap with zero revenue, a $5.79M working capital deficit, and substantial doubt about its ability to continue as a going concern per its Q3 2026 10-Q filing.
ABV-1504 appears to be in preclinical or very early-stage development; no clinical trial records were found in the SecBot or ClinicalTrials.gov databases, meaning it is years away from any potential approval.
The company has relied on dilutive convertible note financings (e.g., $3.39M private placement in October 2026) and has a $100M S-3 shelf registration, signaling ongoing shareholder dilution.
ABVC's stock has fallen ~70% over the past 12 months, trading near its 52-week low of $0.707, reflecting weak investor confidence in its pipeline.

Upcoming Catalysts

  • Potential clinical trial initiation announcement for ABV-1504
  • Licensing milestone payments from Xinnovation Therapeutics
  • Additional patent grants in other territories

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ABVC BIOPHARMA, INC. 424B4 ABVC ·Originating report

Sources · 4

Hover a chip for the title
1 markets.financialcontent.com2 seekingalpha.com3 nasdaq.com4 msn.com